Connor, Clark & Lunn Investment Management (CC&L)’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-83,600
| Closed | -$492K | – | 1552 |
|
|
2023
Q4 | $492K | Sell |
83,600
-142,288
| -63% | -$837K | ﹤0.01% | 1050 |
|
|
2023
Q3 | $2.2M | Sell |
225,888
-50,194
| -18% | -$489K | 0.01% | 593 |
|
|
2023
Q2 | $3.27M | Buy |
276,082
+1,167
| +0.4% | +$13.8K | 0.02% | 480 |
|
|
2023
Q1 | $2.97M | Buy |
274,915
+1,931
| +0.7% | +$20.8K | 0.02% | 471 |
|
|
2022
Q4 | $3.16M | Buy |
272,984
+12,689
| +5% | +$147K | 0.02% | 447 |
|
|
2022
Q3 | $3.88M | Buy |
260,295
+86,087
| +49% | +$1.28M | 0.03% | 370 |
|
|
2022
Q2 | $1.57M | Buy |
+174,208
| New | +$1.57M | 0.01% | 519 |
|